BRAFV600E cooperates with CDX2 inactivation to promote serrated colorectal tumorigenesis

Abstract

While 20-30% of colorectal cancers (CRCs) may arise from precursors with serrated glands, only 8-10% of CRCs manifest serrated morphology at diagnosis. Markers for distinguishing CRCs arising from 'serrated' versus 'conventional adenoma' precursors are lacking. We studied 36 human serrated CRCs and found CDX2 loss or BRAF mutations in ~60% of cases and often together (p= .04). CDX2Null/BRAFV600E expression in adult mouse intestinal epithelium led to serrated morphology tumors (including carcinomas) and BRAFV600E potently interacted with CDX2 silencing to alter gene expression. Like human serrated lesions, CDX2Null/BRAFV600E-mutant epithelium expressed gastric markers. Organoids from CDX2Null/BRAFV600E-mutant colon epithelium showed serrated features, and partially recapitulated the gene expression pattern in mouse colon tissues. We present a novel mouse tumor model based on signature defects seen in many human serrated CRCs - CDX2 loss and BRAFV600E. The mouse intestinal tumors show significant phenotypic similarities to human serrated CRCs and inform about serrated CRC pathogenesis.

Data availability

The following data sets were generated

Article and author information

Author details

  1. Naoya Sakamoto

    Department of Internal Medicine, University of Michigan, Ann Arbor, United States
    Competing interests
    No competing interests declared.
  2. Ying Feng

    Department of Internal Medicine, University of Michigan, Ann Arbor, United States
    Competing interests
    No competing interests declared.
  3. Carmine Stolfi

    Department of Internal Medicine, University of Michigan, Ann Arbor, United States
    Competing interests
    No competing interests declared.
  4. Yuki Kurosu

    Department of Internal Medicine, University of Michigan, Ann Arbor, United States
    Competing interests
    No competing interests declared.
  5. Maranne Green

    Department of Internal Medicine, University of Michigan, Ann Arbor, United States
    Competing interests
    No competing interests declared.
  6. Jeffry Lin

    Department of Internal Medicine, University of Michigan, Ann Arbor, United States
    Competing interests
    No competing interests declared.
  7. Megan Green

    Department of Internal Medicine, University of Michigan, Ann Arbor, United States
    Competing interests
    No competing interests declared.
  8. Kazuhiro Sentani

    Department of Molecular Pathology, Hiroshima University, Hirosima, Japan
    Competing interests
    No competing interests declared.
  9. Wataru Yasui

    Department of Molecular Pathology, Hiroshima University, Hirosima, Japan
    Competing interests
    No competing interests declared.
  10. Martin McMahon

    Department of Dermatology, University of Utah Medical Schoo, Salt Lake City, United States
    Competing interests
    Martin McMahon, Reviewing editor, eLife.
  11. Karin M Hardiman

    Department of Surgery, University of Michigan, Ann Arbor, United States
    Competing interests
    No competing interests declared.
  12. Jason R Spence

    Department of Internal Medicine, University of Michigan, Ann Arbor, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7869-3992
  13. Nobukatsu Horita

    Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, United States
    Competing interests
    No competing interests declared.
  14. Joel K Greenson

    Department of Pathology, University of Michigan, Ann Arbor, United States
    Competing interests
    No competing interests declared.
  15. Rork Kuick

    Department of Biostatistics, University of Michigan, Ann Arbor, United States
    Competing interests
    No competing interests declared.
  16. Kathy R Cho

    Department of Internal Medicine, University of Michigan, Ann Arbor, United States
    Competing interests
    No competing interests declared.
  17. Eric R Fearon

    Department of Internal Medicine, University of Michigan, Ann Arbor, United States
    For correspondence
    fearon@umich.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2867-3971

Funding

National Institutes of Health (R01CA082223)

  • Eric R Fearon

National Institutes of Health (R01CA176839)

  • Martin McMahon

National Institutes of Health (P30CA046592)

  • Eric R Fearon

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Procedures involving mice for the research described herein have been approved by the University of Michigan's Institutional Animal Care and Use Committee (PRO00005075) and were carried out according to Michigan state and US federal regulations.

Human subjects: The colorectal cancers were studied in accordance with the Ethical Guidelines for Human Genome/Gene Research enacted by the Japanese Government. We also studied human benign serrated colorectal lesions obtained from the University of Michigan tissue procurement service through an Institutional Review Board-approved protocol (#00058054).

Copyright

© 2017, Sakamoto et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,715
    views
  • 806
    downloads
  • 79
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Naoya Sakamoto
  2. Ying Feng
  3. Carmine Stolfi
  4. Yuki Kurosu
  5. Maranne Green
  6. Jeffry Lin
  7. Megan Green
  8. Kazuhiro Sentani
  9. Wataru Yasui
  10. Martin McMahon
  11. Karin M Hardiman
  12. Jason R Spence
  13. Nobukatsu Horita
  14. Joel K Greenson
  15. Rork Kuick
  16. Kathy R Cho
  17. Eric R Fearon
(2017)
BRAFV600E cooperates with CDX2 inactivation to promote serrated colorectal tumorigenesis
eLife 6:e20331.
https://doi.org/10.7554/eLife.20331

Share this article

https://doi.org/10.7554/eLife.20331

Further reading

    1. Cancer Biology
    Qianqian Ju, Wenjing Sheng ... Cheng Sun
    Research Article

    TAK1 is a serine/threonine protein kinase that is a key regulator in a wide variety of cellular processes. However, the functions and mechanisms involved in cancer metastasis are still not well understood. Here, we found that TAK1 knockdown promoted esophageal squamous cancer carcinoma (ESCC) migration and invasion, whereas TAK1 overexpression resulted in the opposite outcome. These in vitro findings were recapitulated in vivo in a xenograft metastatic mouse model. Mechanistically, co-immunoprecipitation and mass spectrometry demonstrated that TAK1 interacted with phospholipase C epsilon 1 (PLCE1) and phosphorylated PLCE1 at serine 1060 (S1060). Functional studies revealed that phosphorylation at S1060 in PLCE1 resulted in decreased enzyme activity, leading to the repression of phosphatidylinositol 4,5-bisphosphate (PIP2) hydrolysis. As a result, the degradation products of PIP2 including diacylglycerol (DAG) and inositol IP3 were reduced, which thereby suppressed signal transduction in the axis of PKC/GSK-3β/β-Catenin. Consequently, expression of cancer metastasis-related genes was impeded by TAK1. Overall, our data indicate that TAK1 plays a negative role in ESCC metastasis, which depends on the TAK1-induced phosphorylation of PLCE1 at S1060.

    1. Cancer Biology
    2. Cell Biology
    Rui Hua, Jean X Jiang
    Insight

    Cell crowding causes high-grade breast cancer cells to become more invasive by activating a molecular switch that causes the cells to shrink and spread.